Sign In
Buy AZN
$176.43
+1.50 (+0.86%)
At Close: Jun 22, 2026
Astrazeneca (AZN) Stock Drops Despite Market Gains: Important Facts to Note
07:16pm, Thursday, 18'th Jun 2026
Astrazeneca (AZN) concluded the recent trading session at $174.93, signifying a -1.66% move from its prior day's close.
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Ozempic Linked To Lower Risk Of Violence In New Study
11:45am, Wednesday, 17'th Jun 2026
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New J
FDA Accepts AstraZeneca's Filing for Expanded Use of Ultomiris
01:56pm, Tuesday, 16'th Jun 2026
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus placebo.
AstraZeneca Stock Down 7% in 3 Months: Should You Buy, Sell or Hold?
11:10am, Tuesday, 16'th Jun 2026
AZN shares fell after a camizestrant setback, but blockbuster drugs, oncology growth and a deep pipeline support long-term targets.
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
10:00am, Monday, 15'th Jun 2026
AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone and prednisone has been approved in the US as the first and only targeted treatment for adult p
Astrazeneca (AZN) Outperforms Broader Market: What You Need to Know
07:17pm, Thursday, 11'th Jun 2026
In the most recent trading session, Astrazeneca (AZN) closed at $182.28, indicating a +1.86% shift from the previous trading day.
BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
02:20am, Thursday, 11'th Jun 2026
BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m.
JNJ and AZN Face Patent Headwinds: Which Stock Looks Stronger Now?
12:06pm, Tuesday, 09'th Jun 2026
J&J's diversified healthcare business and growth outlook help it stand out against AstraZeneca despite patent and legal challenges.
AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials
11:46am, Tuesday, 09'th Jun 2026
AstraZeneca Plc (NASDAQ:AZN) is advancing its oral GLP-1 receptor agonist, elecoglipron, into an extensive Phase 3 development program after the drug delivered significant weight-loss and diabetes-con
AstraZeneca's obesity drug shows promise as analysts see upside beyond consensus
09:35am, Tuesday, 09'th Jun 2026
AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental weight-loss pill delivered encouraging mid-stage trial results, prompting investors
AstraZeneca obesity pill helps patients lose 10.5% of body weight in trial
04:16pm, Monday, 08'th Jun 2026
AstraZeneca said on Monday that patients lost 10.5% of their body weight after 26 weeks in a mid-stage trial of its experimental obesity pill, as the drugmaker seeks to challenge Novo Nordisk and E
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
06:26pm, Friday, 05'th Jun 2026
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of success in costly clinical trials.
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
09:00am, Friday, 05'th Jun 2026
NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History PR Newswire NEW YORK, June 5, 2026
